Summary
Global Markets Direct’s, ‘Momenta Pharmaceuticals, Inc. - Product Pipeline Review - 2016’, provides an overview of the Momenta Pharmaceuticals, Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Momenta Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Momenta Pharmaceuticals, Inc.
- The report provides overview of Momenta Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Momenta Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Momenta Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Momenta Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Momenta Pharmaceuticals, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Momenta Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Momenta Pharmaceuticals, Inc. Snapshot 6
Momenta Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Momenta Pharmaceuticals, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Momenta Pharmaceuticals, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Momenta Pharmaceuticals, Inc. - Pipeline Products Glance 12
Momenta Pharmaceuticals, Inc. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Momenta Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Momenta Pharmaceuticals, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Momenta Pharmaceuticals, Inc. - Drug Profiles 17
adalimumab biosimilar 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
necuparanib 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
M-281 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
abatacept biosimilar 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Antibody for Autoimmune Disorders and Inflammation 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
M-230 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
M-615 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
M-706 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
M-710 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
M-730 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
M-740 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibodies for Autoimmune Diseases 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Momenta Pharmaceuticals, Inc. - Pipeline Analysis 30
Momenta Pharmaceuticals, Inc. - Pipeline Products by Target 30
Momenta Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 31
Momenta Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 32
Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 33
Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates 34
Momenta Pharmaceuticals, Inc. - Dormant Projects 39
Momenta Pharmaceuticals, Inc. - Discontinued Pipeline Products 40
Discontinued Pipeline Product Profiles 40
bevacizumab biosimilar 40
Momenta Pharmaceuticals, Inc. - Company Statement 41
Momenta Pharmaceuticals, Inc. - Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Appendix 44
Methodology 44
Coverage 44
Secondary Research 44
Primary Research 44
Expert Panel Validation 44
Contact Us 44
Disclaimer 45
List of Tables
Momenta Pharmaceuticals, Inc., Key Information 6
Momenta Pharmaceuticals, Inc., Key Facts 6
Momenta Pharmaceuticals, Inc. - Pipeline by Indication, 2016 8
Momenta Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10
Momenta Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11
Momenta Pharmaceuticals, Inc. - Phase III, 2016 12
Momenta Pharmaceuticals, Inc. - Phase II, 2016 13
Momenta Pharmaceuticals, Inc. - Phase I, 2016 14
Momenta Pharmaceuticals, Inc. - Preclinical, 2016 15
Momenta Pharmaceuticals, Inc. - Discovery, 2016 16
Momenta Pharmaceuticals, Inc. - Pipeline by Target, 2016 30
Momenta Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 31
Momenta Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 32
Momenta Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016 33
Momenta Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016 34
Momenta Pharmaceuticals, Inc. - Dormant Developmental Projects,2016 39
Momenta Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016 40
Momenta Pharmaceuticals, Inc., Subsidiaries 43
List of Figures
Momenta Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016 8
Momenta Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016 10
Momenta Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016 11
Momenta Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2016 30
Momenta Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016 31
Momenta Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016 32
Momenta Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 33
